Previous 10 | Next 10 |
Mind Medicine (NASDAQ:MNMD) announced that its Chief Technology Officer, Bradford Cross, has transitioned from his role. Additionally, Don Gehlert, PhD will be transitioning from his role as CSO and will continue as a Senior Scientific Advisor. "We remain dedicated to advancing our pipeline a...
MindMed Announces Transitions to Management Team Canada NewsWire - Bradford Cross , Chief Technology Officer to transition; Don Gehlert , PhD, Chief Scientific Officer to transition to Senior Scientific Advisor - NEW YORK , Dec. 29, 2021 /CNW/ -- ...
This year hasn't been easy for MindMed (NASDAQ:MNMD), which has faced its shares of struggles and is down 46% year to date. A week ago, the FDA placed a clinical hold on its IND submission necessary to begin a phase 2b trial of LSD for generalized anxiety disorder. On the positive s...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips When most people think of anxiety disorders, they likely don’t think of psychedelic drugs. But that’s exactly how MindMed (NASDAQ: MNMD ) is seeking to treat generalized anxiety disorder. The innovative ...
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder Canada NewsWire - FDA has issued a clinical hold on initial IND submission required to initiate Phase 2b trial of LSD for the treatment of generalized ...
MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD Canada NewsWire - Enrolling patients in proof-of-concept exploratory trial conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht University in the Nethe...
Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (“MindMed”), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a psychedelic drug impacts the substance’s effects. Microdosing refers t...
Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A nove...
Mind Medicine (NASDAQ:MNMD) has appointed Robert Barrowas CEO and as a member of the board, effective immediately. Barrow previously served as interim CEO and Chief Development Officer of MindMed and brings strategic expertise and deep industry insight to his role. Robert Barrow is an accompl...
MindMed Appoints Robert Barrow as Chief Executive Officer and Director Canada NewsWire -Mr. Barrow previously served as interim Chief Executive Officer and Chief Development Officer of MindMed - Carol Vallone appointed as Chair of the Board of Directors, ...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Stephanie Fagan, effective today, as Chief Corpo...
2024-07-26 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...